Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612081 | 0.81 | SLC18A3 (0.39) | CA1CA2CA4CTSKSLC18A3 | |
| SCHEMBL612530 | 0.80 | NOS1 (0.33) | — | |
| SCHEMBL10235868 | 0.78 | CA1 (0.49) | CA1CA2CA4CTSKSLC18A3 | |
| SCHEMBL10235823 | 0.77 | CA1 (0.42) | CA1CA2CA4 | |
| SCHEMBL11474308 | 0.76 | SLC18A3 (0.51) | CA1CA2CA4CTSKSLC18A2 | |
| SCHEMBL14979616 | 0.75 | MEN1 (0.43) | CA1CA2CA4CTSKSLC18A3 | |
| SCHEMBL3868004 | 0.74 | EPHX1 (0.35) | PTGFR | |
| SCHEMBL608470 | 0.73 | KCNH2 (0.44) | — | |
| SCHEMBL18440461 | 0.73 | SLC18A2 (0.54) | SLC18A2SLC18A3 | |
| SCHEMBL22350147 | 0.70 | PTGER1 (0.49) | SCN9APTGFRSLC18A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | CA1 4855/4885CA2 3441/4885CA4 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.